BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 15743203)

  • 1. 3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies.
    Peng Y; Keenan SM; Zhang Q; Kholodovych V; Welsh WJ
    J Med Chem; 2005 Mar; 48(5):1620-9. PubMed ID: 15743203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D-QSAR comparative molecular field analysis on delta opioid receptor agonist SNC80 and its analogs.
    Peng Y; Keenan SM; Zhang Q; Welsh WJ
    J Mol Graph Model; 2005 Sep; 24(1):25-33. PubMed ID: 15950508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
    Metzger TG; Paterlini MG; Ferguson DM; Portoghese PS
    J Med Chem; 2001 Mar; 44(6):857-62. PubMed ID: 11300867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing ligand recognition of the opioid pan antagonist AT-076 at nociceptin, kappa, mu, and delta opioid receptors through structure-activity relationships.
    Journigan VB; Polgar WE; Tuan EW; Lu J; Daga PR; Zaveri NT
    Sci Rep; 2017 Oct; 7(1):13255. PubMed ID: 29038479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of estrogen receptor alpha and beta subtypes based on comparative molecular field analysis (CoMFA).
    Xing L; Welsh WJ; Tong W; Perkins R; Sheehan DM
    SAR QSAR Environ Res; 1999; 10(2-3):215-37. PubMed ID: 10491851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of the message-address concept to the docking of naltrexone and selective naltrexone-derived opioid antagonists into opioid receptor models.
    Metzger TG; Paterlini MG; Portoghese PS; Ferguson DM
    Neurochem Res; 1996 Nov; 21(11):1287-94. PubMed ID: 8947918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QSAR study of a large set of 3-pyridyl ethers as ligands of the alpha4beta2 nicotinic acetylcholine receptor.
    Zhang H; Li H; Ma Q
    J Mol Graph Model; 2007 Jul; 26(1):226-35. PubMed ID: 17208024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A chimeric analysis of the opioid receptor domains critical for the binding selectivity of mu opioid ligands.
    Watson B; Meng F; Akil H
    Neurobiol Dis; 1996 Feb; 3(1):87-96. PubMed ID: 9173916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular modeling and 3D-QSAR studies of indolomorphinan derivatives as kappa opioid antagonists.
    Li W; Tang Y; Zheng YL; Qiu ZB
    Bioorg Med Chem; 2006 Feb; 14(3):601-10. PubMed ID: 16202615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural biology: How opioid drugs bind to receptors.
    Filizola M; Devi LA
    Nature; 2012 May; 485(7398):314-7. PubMed ID: 22596150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative structure-activity relationship of rubiscolin analogues as delta opioid peptides using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA).
    Caballero J; Saavedra M; Fernández M; González-Nilo FD
    J Agric Food Chem; 2007 Oct; 55(20):8101-4. PubMed ID: 17803260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the structure of opioid receptors with homology modeling based on single and multiple templates and subsequent docking: a comparative study.
    Bera I; Laskar A; Ghoshal N
    J Mol Model; 2011 May; 17(5):1207-21. PubMed ID: 20661609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of 4-(N,N-diarylamino)piperidines with high selectivity to the delta-opioid receptor: a combined 3D-QSAR and ligand docking study.
    Podlogar BL; Poda GI; Demeter DA; Zhang SP; Carson JR; Neilson LA; Reitz AB; Ferguson DM
    Drug Des Discov; 2000; 17(1):34-50. PubMed ID: 10928448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular determinants of non-specific recognition of delta, mu, and kappa opioid receptors.
    Filizola M; Villar HO; Loew GH
    Bioorg Med Chem; 2001 Jan; 9(1):69-76. PubMed ID: 11197347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
    Baker AK; Meert TF
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D modeling, ligand binding and activation studies of the cloned mouse delta, mu; and kappa opioid receptors.
    Filizola M; Laakkonen L; Loew GH
    Protein Eng; 1999 Nov; 12(11):927-42. PubMed ID: 10585498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The design of delta-selective opioid receptor antagonists.
    Portoghese PS
    Farmaco; 1993 Feb; 48(2):243-51. PubMed ID: 8388215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure based 3D-QSAR studies of Interleukin-2 inhibitors: Comparing the quality and predictivity of 3D-QSAR models obtained from different alignment methods and charge calculations.
    Halim SA; Zaheer-ul-Haq
    Chem Biol Interact; 2015 Aug; 238():9-24. PubMed ID: 26051521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes.
    Portoghese PS
    J Med Chem; 2001 Jul; 44(14):2259-69. PubMed ID: 11428919
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.